NYSE$CRL
Charles River Laboratories International Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Charles River Labs' performance was impacted by lower revenue in DSA and RMS segments, offset by growth in Manufacturing Solutions, with revised guidance reflecting weaker demand trends.
Charles River Laboratories reported a 3.2% decrease in second-quarter revenue to $1.03 billion, driven by declines in Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments, partially offset by growth in Manufacturing Solutions. GAAP EPS was $1.74, while non-GAAP EPS was $2.80. The company revised its 2024 guidance due to softer demand trends, particularly from biopharmaceutical clients.
- Second-quarter revenue decreased by 3.2% to $1.03 billion, with organic revenue also declining by 3.2%.
- GAAP operating margin decreased to 14.8%, while non-GAAP operating margin increased to 21.3%.
- GAAP EPS decreased to $1.74, while non-GAAP EPS increased to $2.80.
- The company's Board of Directors approved a new stock repurchase authorization of $1.0 billion.
Headline financials
Revenue & EPS history
Charles River Labs · Revenue · Quarterly
$1.03B
Revenue by segment
Charles River Labs · $1.03B total across 3 segments · Q3 2023
- Discovery & Safety Assessment$664M+7.2%64.7%
- Research Models & Services$187M+3.7%18.2%
- Manufacturing Solutions$176M-7.3%17.1%
Forward guidance
Charles River Laboratories revised its 2024 financial guidance due to the lack of recovery in demand from small and mid-sized biotechnology clients and softer demand trends from global biopharmaceutical clients.
Tailwinds
- Implementing restructuring initiatives expected to result in over $150 million in annualized cost savings.
- Approximately $100 million of the cost savings will be realized in 2024.
- Aggressively managing cost structure.
- Initiating new and innovative ways to transform the business.
- Enhancing commercial efforts to win new business.
Headwinds
- Revenue growth, reported is expected to be between (4.5)% – (2.5)%.
- Organic revenue growth is expected to be between (5.0)% – (3.0)%.
- GAAP EPS estimate is revised to $5.65 – $5.95.
- Non-GAAP EPS estimate is revised to $9.90 – $10.20.
- The reduced guidance primarily reflects the lack of a recovery in demand from our small and mid-sized biotechnology clients in the second half of the year, as well as softer demand trends from global biopharmaceutical clients whose deterioration has become increasingly evident in the past couple of months.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+0.1%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+0.7%
Avg return
30 days after
47%
32 / 68 earnings
Positive
+18.4%
Q1 2025
Best reaction
-13.3%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.8% | -9.0% | -0.1% | |
| Q4 2025 | -1.8% | +3.1% | -3.1% | |
| Q3 2025 | -5.5% | -5.0% | +3.6% | |
| Q1 2025 | +18.4% | +24.0% | +25.4% | |
| Q4 2024 | +6.9% | +10.4% | +8.3% | |
| Q3 2024 | +11.5% | +17.0% | +1.7% | |
| Q2 2024 | -11.7% | -15.1% | -17.8% | |
| Q1 2024 | -3.0% | -1.0% | -8.7% | |
| Q4 2023 | +11.4% | +11.2% | +17.6% | |
| Q3 2023 | -7.3% | -7.0% | +11.8% | |
| Q2 2023 | +5.5% | +5.2% | -3.2% | |
| Q1 2023 | +2.7% | +1.0% | +6.1% | |
| Q4 2022 | -6.7% | -9.0% | -20.4% | |
| Q3 2022 | +4.8% | +9.0% | +7.4% | |
| Q2 2022 | -6.6% | -9.4% | -17.8% | |
| Q1 2022 | -1.2% | -8.9% | -3.3% | |
| Q4 2021 | -6.7% | -6.1% | -8.3% | |
| Q3 2021 | -12.2% | -13.4% | -17.3% | |
| Q2 2021 | -0.3% | -0.4% | +9.3% | |
| Q1 2021 | +4.0% | +3.2% | -0.1% | |
| Q4 2020 | +2.0% | -1.1% | -0.0% | |
| Q3 2020 | +2.6% | +7.0% | +3.7% | |
| Q2 2020 | +6.8% | +7.3% | +0.4% | |
| Q1 2020 | +11.1% | +12.0% | +24.2% | |
| Q4 2019 | +8.6% | +11.9% | -21.3% | |
| Q3 2019 | -2.5% | +1.1% | +12.0% | |
| Q2 2019 | -5.1% | -10.3% | -7.0% | |
| Q1 2019 | -4.2% | -4.1% | -10.4% | |
| Q4 2018 | +8.1% | +9.0% | +11.1% | |
| Q3 2018 | +8.8% | +6.8% | +3.0% | |
| Q2 2018 | -5.2% | -6.6% | -1.6% | |
| Q1 2018 | +0.3% | -1.0% | +8.5% | |
| Q4 2017 | +8.2% | +6.0% | +9.9% | |
| Q3 2017 | -13.3% | -14.3% | -11.9% | |
| Q2 2017 | -1.7% | -0.2% | +10.0% | |
| Q1 2017 | -3.8% | -2.3% | +2.8% | |
| Q4 2016 | +7.6% | +7.3% | +8.4% | |
| Q3 2016 | -9.0% | -5.1% | -3.0% | |
| Q2 2016 | -0.0% | -3.1% | -3.0% | |
| Q1 2016 | +2.5% | — | — | |
| Q4 2015 | +3.9% | — | — | |
| Q3 2015 | +5.7% | — | — | |
| Q2 2015 | +1.4% | — | — | |
| Q1 2015 | -8.8% | — | — | |
| Q4 2014 | +6.3% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | +6.0% | — | — | |
| Q1 2014 | -6.6% | — | — | |
| Q4 2013 | -1.6% | — | — | |
| Q3 2013 | -1.2% | — | — | |
| Q2 2013 | +3.4% | — | — | |
| Q1 2013 | -3.9% | — | — | |
| Q4 2012 | +0.9% | — | — | |
| Q3 2012 | -5.3% | — | — | |
| Q2 2012 | +2.3% | — | — | |
| Q1 2012 | +1.8% | — | — | |
| Q4 2010 | -1.3% | — | — | |
| Q4 2011 | -1.3% | — | — | |
| Q3 2011 | -5.0% | — | — | |
| Q2 2011 | -9.4% | — | — | |
| Q1 2010 | -2.4% | — | — | |
| Q1 2011 | -0.1% | — | — | |
| Q4 2008 | -0.9% | — | — | |
| Q3 2010 | -4.4% | — | — | |
| Q3 2009 | -4.4% | — | — | |
| Q2 2010 | +3.6% | — | — | |
| Q4 2009 | +3.6% | — | — | |
| Q2 2009 | +3.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro